Searchable abstracts of presentations at key conferences in endocrinology

ea0037ep598 | Obesity and cardiovascular endocrinology | ECE2015

TNFα induces lipolysis by downregulating CIDEC via MEK/ERK-dependent PPARγ phosphorylation and nuclear exportation

Tan Xinrui , zhang Meizhen , Xiao Yanfeng

CIDEC is a lipid droplet-targeting protein that promotes triglyceride accumulation and inhibits lipolysis. CIDEC is regulated by peroxisome proliferator-activated receptor γ (PPARγ). Previous studies demonstrate that CIDEC down-regulation is involved in TNFα-induced lipolysis. Here, we focus on the signalling pathway to clarify the mechanism of TNFα-mediated CIDEC down-regulation. CIDEC is significantly decreased in subcutaneous adipose tissue in obese subj...

ea0063gp162 | Cushing's | ECE2019

Pharmacokinetics of osilodrostat following single and multiple doses of osilodrostat in healthy subjects and patients with Cushing’s disease

Han Kevin , Tauchmanova Libuse , Atkinson Susan , Darstein Christelle , Zhang Xinrui , Combes Francois Pierre , Pedroncelli Alberto M

Introduction: Osilodrostat is a potent oral 11β-hydroxylase inhibitor currently in Phase III clinical development for the treatment of Cushing’s syndrome (CS). The key pharmacokinetic (PK) properties, drug–drug interactions (DDIs), and population PK findings for osilodrostat in humans are summarized.Methods: Osilodrostat PK has been characterized in nine Phase I studies (healthy subjects and subjects with hepatic or renal impairment), two ...